Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 1/20 | 0.51 |
| ▸ | F3 | P13726 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.46 |
| ▸ | NHERF1 | O14745 | 5/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | MMP14 | P50281 | 1/20 | 0.42 |
| ▸ | PYGL | P06737 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28847710 | 0.82 | F7 (0.61) | F7F3NR4A2STING1NHERF1 | |
| SCHEMBL7902669 | 0.81 | MTNR1A (0.57) | F7F3NR4A2STING1NHERF1 | |
| SCHEMBL30386394 | 0.81 | F7 (0.55) | F7F3NR4A2STING1NHERF1 | |
| SCHEMBL23167610 | 0.79 | F7 (0.58) | F7F3NR4A2STING1NHERF1 | |
| SCHEMBL24630105 | 0.78 | NR4A2 (0.54) | F7F3NR4A2STING1NHERF1 | |
| SCHEMBL30885411 | 0.78 | STING1 (0.70) | STING1NHERF1 | |
| SCHEMBL12545431 | 0.77 | NR4A2 (0.52) | F7F3NR4A2STING1NHERF1 | |
| SCHEMBL30218664 | 0.77 | NR4A2 (0.52) | F7F3NR4A2STING1NHERF1 | |
| SCHEMBL28991331 | 0.76 | STING1 (0.52) | F7F3STING1 | |
| SCHEMBL30386339 | 0.76 | STING1 (0.52) | F7F3STING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037325-B2 | 1,2-diaminobenzimidazole derivative | CARNA BIOSCIENCES, INC. (JP) | 2024-07-16 | — | — | US | disclosed |
| US-12037325-B2 | 1,2-diaminobenzimidazole derivative | CARNA BIOSCIENCES, INC. (JP) | 2024-07-16 | — | — | US | disclosed |
| US-12037325-B2 | 1,2-diaminobenzimidazole derivative | CARNA BIOSCIENCES, INC. (JP) | 2024-07-16 | — | — | US | disclosed |
| EP-4373811-A1 | NOVEL 1,2-DIAMINOBENZIMIDAZOLE DERIVATIVE | Carna Biosciences, Inc. (JP) | 2024-05-29 | — | — | EP | disclosed |
| WO-2023053039-A1 | NOVEL DIAMINOBENZIMIDAZOLE DERIVATIVE | CARNA BIOSCIENCES, INC. (JP) | 2023-04-06 | — | — | WO | disclosed |
| US-20230097964-A1 | NOVEL 1,2-DIAMINOBENZIMIDAZOLE DERIVATIVE | CARNA BIOSCIENCES, INC. (JP) | 2023-03-30 | — | — | US | disclosed |
| WO-2023002246-A1 | NOVEL 1,2-DIAMINOBENZIMIDAZOLE DERIVATIVE | CARNA BIOSCIENCES, INC. (JP) | 2023-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037325-B2 | 1,2-diaminobenzimidazole derivative | STING1, TBK1, IRF3 | F7 4728/4885F3 1905/4885NR4A2 953/4885 |
| US-20230097964-A1 | NOVEL 1,2-DIAMINOBENZIMIDAZOLE DERIVATIVE | STING1, IRF3, TBK1 | F7 4595/4885F3 1894/4885NR4A2 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.